Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related mortality. Exploration of the tumor microenvironment (TME) has resulted in dramatic advancements in the treatment of NSCLC through the advent of immunotherapy. Indeed, anti-programmed death (PD) ligand 1/PD-1 checkpoint inhibitor therapy has substantially improved survival for advanced, unresectable disease and is now being increasingly utilized in the perioperative setting for early-stage, resectable tumors. This success has generated vigorous interest in exploring other cellular players in the NSCLC TME that could be potentially targeted for therapeutic benefit. In this review, we discuss the current state of therapeutic targets in the NSCLC TME, reflect on the revolution of immunotherapy and future directions for its utilization, and reflect on how the current investigations into TME-specific targets may impact thoracic surgical care.
3 February 2024 in Journal of Surgical Case Reports
Treatment of long-segment tracheal defects remains a challenge in thoracic surgery with no standard surgical option. Aortic allografts have been used for this purpose with varying degrees of success. In a patient that suffered anastomotic dehiscence after tracheal resection with primary anastomosis, we performed complete tracheal resection and replacement using a stented circumferential aortic allograft. Currently, this patient is able to breathe normally without tracheostomy assistance 22 months postoperatively. Our report is the first in the English literature of long-term survival without tracheostomy dependence and close interval follow-up after circumferential tracheal resection and replacement with a cryopreserved aortic allograft.
Tricuspid valve infective endocarditis (TVIE) comprises 5–10% of all endocarditis cases and is more prevalent with the recent and ongoing opioid and intravenous drug epidemic, as well as increased placement of intracardiac devices. New technologies have been developed to manage tricuspid valve (TV) vegetations in an evolving population. In this chapter, we provide comprehensive review of age-old treatment modalities for TVIE as well as a discussion of advanced TV repair and replacement modalities and alternatives to surgery. We examine critical management nuances including optimal surgical technique based on a variety of patient-related factors, ideal operative timing, medical and surgical management of septic emboli, managing patients with prior percutaneous TV interventions and current TVIE, and emerging treatment techniques for TVIE. We aim to provide a framework for the multi-disciplinary care of TVIE in a changing patient and technology landscape.